United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will host a webcast to review data from the successful TETON-2 pivotal study evaluating the use of nebulized Tyvaso® ...
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its TETON-2 study evaluating the use of nebulized Tyvaso® (treprostinil) Inhalation Solution for the ...
Figure 1. A, Still frame of angiography, as shown here, demonstrates partial anomalous venous return of the right upper lobe (arrow) into the SVC. B, Still frame of angiography after contrast ...
SUNRISE, Fla., June 03, 2025 (GLOBE NEWSWIRE) -- Transpire Bio Inc., a U.S.-based, integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and ...
Liquidia Corporation has announced that its inhalation powder YUTREPIA™ (treprostinil) is now available for prescription at specialty pharmacies, following FDA approval on May 23, 2025, for treating ...
ABSTRACT: This review focuses on the pulmonary protection strategies during the cooperative period in cardiothoracic surgery. By deeply analyzing the psychophysiology mechanism of pulmonary injury ...
The FDA has approved YUTREPIA™ (treprostinil) inhalation powder, developed by Liquidia Corporation, as a treatment option for adults with pulmonary arterial hypertension (PAH) and pulmonary ...
Introduction: Preterm birth and intrauterine inflammation are commonly associated with lung inflammation and remodeling. We developed a fetal inflammatory response model using increasing doses of ...
MANCHESTER, England — Use of immunosuppressive drugs within 5 years of the onset of systemic sclerosis (SSc) did not lower patients’ risk for developing pulmonary arterial hypertension (PAH) but was ...
The following is a summary of “Right atrial reservoir strain as an early predictor of pulmonary hypertension development in Systemic Sclerosis: a single center pilot study,” published in the April ...
Systemic lupus erythematosus is associated with an increased risk for pulmonary manifestations, including interstitial lung disease and pulmonary hypertension. Systemic lupus erythematosus (SLE) may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback